Reply to: "NAFLD is a predictor of liver injury in COVID-19 hospitalized patients but not of mortality, disease severity on the presentation or progression - The debate continues".
作者信息
Ji Dong, Cheng Gregory, Lau George
机构信息
The Fifth Medical Center of Chinese PLA General Hospital, Beijing 100039, China.
Faculty of Health Science, University of Macau; Humanity and Health Clinical Trial Center, Humanity & Health Medical Group, Hong Kong SAR, China.
出版信息
J Hepatol. 2021 Feb;74(2):484-485. doi: 10.1016/j.jhep.2020.10.020. Epub 2020 Oct 29.
Abstract
摘要
相似文献
1
Reply to: "NAFLD is a predictor of liver injury in COVID-19 hospitalized patients but not of mortality, disease severity on the presentation or progression - The debate continues".回复：“非酒精性脂肪性肝病是新冠住院患者肝损伤的预测指标，但不是死亡率、就诊时疾病严重程度或疾病进展的预测指标——争论仍在继续”
J Hepatol. 2021 Feb;74(2):484-485. doi: 10.1016/j.jhep.2020.10.020. Epub 2020 Oct 29.
2
NAFLD is a predictor of liver injury in COVID-19 hospitalized patients but not of mortality, disease severity on the presentation or progression - The debate continues.非酒精性脂肪性肝病是新冠病毒肺炎住院患者肝损伤的一个预测指标，但不是死亡率、就诊时疾病严重程度或病情进展的预测指标——争论仍在继续。
J Hepatol. 2021 Feb;74(2):482-484. doi: 10.1016/j.jhep.2020.09.006. Epub 2020 Nov 19.
3
Reply to: 'NAFLD or comorbidities, that is the question'.
J Hepatol. 2020 Sep;73(3):724-725. doi: 10.1016/j.jhep.2020.05.006. Epub 2020 May 12.
4
Non-Alcoholic Fatty Liver Disease and COVID-19-Two Pandemics Hitting at the Same Time.非酒精性脂肪性肝病与 COVID-19：双重疫情夹击
Medicina (Kaunas). 2021 Oct 3;57(10):1057. doi: 10.3390/medicina57101057.
5
NAFLD or comorbidities, that is the question.非酒精性脂肪性肝病还是合并症，这才是问题所在。
J Hepatol. 2020 Sep;73(3):723. doi: 10.1016/j.jhep.2020.04.026. Epub 2020 Apr 22.
6
Risk of severe illness from COVID-19 in patients with metabolic dysfunction-associated fatty liver disease and increased fibrosis scores.代谢功能障碍相关脂肪性肝病且纤维化评分升高的患者感染新型冠状病毒肺炎后出现重症的风险。
Gut. 2020 Aug;69(8):1545-1547. doi: 10.1136/gutjnl-2020-321611. Epub 2020 May 15.
7
No evidence for an increased liver uptake of SARS-CoV-2 in metabolic-associated fatty liver disease.在代谢相关脂肪性肝病中，没有证据表明严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的肝脏摄取增加。
J Hepatol. 2020 Sep;73(3):717-718. doi: 10.1016/j.jhep.2020.04.035. Epub 2020 Apr 30.
8
Letter to the Editor: Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease.致编辑的信：肥胖作为代谢相关脂肪性肝病患者中COVID-19病情更严重的危险因素
Metabolism. 2020 Jul;108:154256. doi: 10.1016/j.metabol.2020.154256. Epub 2020 Apr 29.
9
Prevalence of liver injury and correlation with clinical outcomes in patients with COVID-19: systematic review with meta-analysis.新型冠状病毒肺炎患者肝损伤的发生率及其与临床结局的相关性：系统评价与荟萃分析。
Eur Rev Med Pharmacol Sci. 2020 Dec;24(24):13072-13088. doi: 10.26355/eurrev_202012_24215.
10
Comparison of patients hospitalized with COVID-19, H7N9 and H1N1.比较因 COVID-19、H7N9 和 H1N1 住院的患者。
Infect Dis Poverty. 2020 Dec 2;9(1):163. doi: 10.1186/s40249-020-00781-5.
引用本文的文献
1
Clinical implications of COVID-19 in patients with metabolic-associated fatty liver disease.COVID-19 对代谢相关脂肪性肝病患者的临床影响。
World J Gastroenterol. 2023 Jan 21;29(3):487-502. doi: 10.3748/wjg.v29.i3.487.
2
COVID-19 Pandemic: Insights into Interactions between SARS-CoV-2 Infection and MAFLD.COVID-19 大流行：对 SARS-CoV-2 感染与 MAFLD 之间相互作用的深入了解。
Int J Biol Sci. 2022 Jul 11;18(12):4756-4767. doi: 10.7150/ijbs.72461. eCollection 2022.
3
Liver Injury and Elevated FIB-4 Define a High-Risk Group in Patients with COVID-19.肝损伤和FIB-4升高界定了COVID-19患者中的高危群体。
J Clin Med. 2021 Dec 28;11(1):153. doi: 10.3390/jcm11010153.
4
Coronavirus disease 2019 and non-alcoholic fatty liver disease.2019冠状病毒病与非酒精性脂肪性肝病
World J Hepatol. 2021 Sep 27;13(9):969-978. doi: 10.4254/wjh.v13.i9.969.
5
Coronavirus Disease-2019 (COVID-19) and the Liver.2019冠状病毒病（COVID-19）与肝脏
J Clin Transl Hepatol. 2021 Apr 28;9(2):247-255. doi: 10.14218/JCTH.2021.00006. Epub 2021 Mar 22.
6
Severe Acute Respiratory Syndrome Coronavirus-2 Infection in Children With Liver Transplant and Native Liver Disease: An International Observational Registry Study.儿童肝移植和原发性肝病中严重急性呼吸综合征冠状病毒 2 感染：一项国际观察性登记研究。
J Pediatr Gastroenterol Nutr. 2021 Jun 1;72(6):807-814. doi: 10.1097/MPG.0000000000003077.
7
APASL practical recommendations for the management of hepatocellular carcinoma in the era of COVID-19.亚太肝脏研究学会（APASL）在 COVID-19 时代管理肝细胞癌的实用建议。
Hepatol Int. 2020 Dec;14(6):920-929. doi: 10.1007/s12072-020-10103-4. Epub 2020 Nov 11.
Zotero 插件